ClinConnect ClinConnect Logo
Search / Trial NCT00271232

InSync III Marquis Model 7279 Cardioverter Defibrillator Cardiac Resynchronization System

Launched by MEDTRONIC CARDIAC RHYTHM AND HEART FAILURE · Dec 28, 2005

Trial Information

Current as of April 29, 2025

Completed

Keywords

Heart Failure, Cardiac Resynchronization

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subject has, or is at risk of having, a heart beat that is too fast and his/her doctor has determined the need for an implantable cardioverter defibrillator.
  • Subject is on optimal medical treatment for heart failure.
  • Subject has reduced left ventricular ejection fraction (LVEF≤35%). (LVEF is a measurement of how well the left ventricle pumps blood out to the rest of the body. The higher the LVEF the more blood the ventricle is pumping.)
  • Subject who has heart failure which severely limits daily activities (NYHA Class III) or subject who has severe heart failure and should always be resting (NYHA Class IV)
  • Subject who has a QRS≥130ms (The QRS interval is a measurement of how the electrical signal involved in a heart beat travels/conducts through the ventricles. A wide QRS (more than 120 ms) suggests that there is a conduction problem (or block) in the ventricles.)
  • Subjects with a left ventricular end diastolic dimension (LVEDD≥55mm). (The LVEDD is a measurement taken during an echocardiogram that is one indication of the health of the left ventricle.)
  • Exclusion Criteria:
  • Subject has unstable chest pain, heart surgery within past 3 months
  • Subject has liver function tests greater than 3 times normal limits
  • Subject has chronic (permanent) atrial arrhythmias (fast heart beats in the upper chamber(s) of the heart)

About Medtronic Cardiac Rhythm And Heart Failure

Medtronic Cardiac Rhythm and Heart Failure is a leading division of Medtronic, dedicated to advancing innovative therapies for patients with cardiac rhythm disorders and heart failure. With a commitment to improving patient outcomes, this division focuses on developing cutting-edge medical devices and solutions that enhance the management of arrhythmias and heart failure. Leveraging extensive research and clinical expertise, Medtronic Cardiac Rhythm and Heart Failure aims to transform patient care through evidence-based approaches and a robust pipeline of groundbreaking technologies. Their work not only addresses immediate clinical challenges but also contributes to the long-term health and well-being of individuals with complex cardiac conditions.

Locations

Los Angeles, California, United States

Jacksonville, Florida, United States

Atlanta, Georgia, United States

Kansas City, Missouri, United States

Anchorage, Alaska, United States

Tampa, Florida, United States

Kansas City, Kansas, United States

Rochester, New York, United States

Cleveland, Ohio, United States

Columbus, Ohio, United States

Philadelphia, Pennsylvania, United States

Nashville, Tennessee, United States

Milwaukee, Wisconsin, United States

Minneapolis, Minnesota, United States

New York, New York, United States

Dallas, Texas, United States

Phoenix, Arizona, United States

Memphis, Tennessee, United States

Falls Church, Virginia, United States

Rochester, Minnesota, United States

Las Vegas, Nevada, United States

Lincoln, Nebraska, United States

Austin, Texas, United States

Stanford, California, United States

Cincinnati, Ohio, United States

Burlington, Massachusetts, United States

Syracuse, New York, United States

Columbia, Missouri, United States

Lebanon, New Hampshire, United States

Raleigh, North Carolina, United States

Pensacola, Florida, United States

Lancaster, Pennsylvania, United States

Wynnewood, Pennsylvania, United States

St. Paul, Minnesota, United States

Beech Grove, Indiana, United States

Aiken, South Carolina, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials